Publication in Nature journal highlighting clinical findings for an armored autologous GPC3 CAR-T therapy in patients with advanced HCC

Publication in Nature sharing the results of the first-in-human clinical study evaluating the safety and efficacy of C-CAR031, a novel glypican-3 (GPC3)-targeted CAR-T that AbelZeta and AstraZeneca previously partnered to develop in China, and which is now being developed solely by AstraZeneca as AZD7003 The post Publication in Nature journal highlighting clinical findings for an armored autologous GPC3 CAR-T therapy in patients with advanced HCC appeared first on AbelZeta Pharma .